1,720,981 research outputs found
Riječki filološki portreti 2
No full textU knjizi se nalaze uvodna i opća poglavlja (Riječka filološka strujanja ; Riječka filološka škola ; Kroatistika na riječkom sveučilištu) i filološki portreti (Fran Kurelac ; Ivan Dežman ; Šime Starčević ; Adolfo Veber Tkalčević ; Šime Ljubić ; Ljudevit Jonke ; Iva Lukežić ; Marija Turk)
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Get PDFWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Get PDFWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Author-wise bibliometric analysis based on entropy.
No full textAuthor-wise bibliometric analysis based on entropy.</p
Cellular immune response during therapy of chronic HCV virus infection
No full textUvod. HCV specifični T stanični odgovor i uspješna migracija specifičnih
T limfocita prema jetri bitna je za kontrolu HCV virusne infekcije, dok je
prisustvo nespecifičnih inflamatornih stanica povezano s jetrenim oštećenjem.
Interakcija specifičnih T limfocita s kemokinima i njihovo privlačenje prema
mjestu upale ključna je točka pokretanja imunološkog odgovora u HCV infekciji. ----- Cilj i metode: cilj studije bio je analizirati kinetiku HCV specifične stanične
imunosti i kemokina CXCL9, CXCL10 i CXCL11 tijekom liječenja kroničng
hepatitisa C pegiliranim interferonom i ribavirinom. Praćena je dinamika
kemokina prije i u toku liječenja obzirom na uspjeh terapije. Također je praćena
korelacija frekvencija HCV NS3 specifičnih CD8+ limfocita i virusne kinetike
posebno u ranom periodu liječenja. Osnovi cilj bio je utvrditi da li postoji
korelacija između visine pojedinih kemokina i odgovora na terapiju. Praćena je
korelacija između odabranih upalnih parametara, virusne kinetike, kretanja
koncentracije kemokina u različitim vremenskim točkama liječenja (0, 4,12 i 24
tjedna) a u odnosu SVR. ----- Rezultati: 46 bolesnika s kroničnom infekcijom i genotipom 1 praćeno je
u toku terapije pegiliranim interferonom i ribavirinom. Koncentracije CXCL10 na
početku terapije više su u bolesnika koji na kraju neće imati protrahirano dobar
odgovor (non-SVR n=20, SVR n=26) Povišene vrijednosti CXCL10 također su
pozitivnoj korelaciji su sa dobi, viremijom, stupnjem fibroze i upalnom aktivnosti
ali je multivarijatna analiza pokazala najveći OD upravo za SVR ili non-SVR.
Povišene početne vrijednosti CXCL10 imaju pozitivnu predikcijsku vrijednost za
non-SVR (ROC P=0,7942) . Koncentracije CXCL10 nakon 4 tjedna terapije još
su više u bolesnika s non-SVR (ROC P=0,9288). Povišene vrijednosti CXCL10
nakon 4 tj. terapije predstavljaju najbolju pozitivnu predikcijsku vrijednosti za
non-SVR. Koncentracija CXCL10 >252pg/ml nakon 4 tjedna terapije ima
osjetljivost 81,8% i specifičnost 91,7% u predikciji krajnjeg neuspjeha terapije, a
te vrijednosti imaju bolju pozitivnu predikcijsku vrijednost za neuspjeh terapije
nego dob bolesnika, ili stupanj fibroze (F1-3 vs F4-6).
Koncentracije CXCL9 također više su u non-SVR bolesnika, dok koncentracije
CXCL11 nisu pokazale značajnu dinamiku niti predikcijsku vrijednost za SVR.
Kemokinski odgovor tj visina koncentracije kemokina u toku terapije kroničnog
hepatitisa C pegiliranim interferonom alfa2b razlikuje se za sva tri ispitivana
kemokina. Kod CXCL9 nalazimo smanjivanje od bazičnih vrijednosti ali održanu
razliku između SVR i non-SVR grupe (118 pg/ml vs 176 pg/ml nakon 4 tjedna)
te također kasnije u toku liječenja. Kod CXCL10 izraženija je dihotomija izmađu
SVR i non-SVR grupe na početku terapije i naročito nakon 4 tjedna terapije pa
je u non-SVR grupi CXCL10 u porastu od početnog medijana 395 pg/ml na 424
pg/ml, a u SVR grupi pada sa početnih 285pg/ml na 156pg/ml. Nakon 12 i 24
tjedna vrijednosti CXCL10 za SVR i non-SVR grupu su u smanjivanju ali
međusobne razlike koncentracije su značajne.
Medijan postotka HCV NS3CINGVCWTV-specifični CD8+ T-limfocita u
perifernoj krvi prije liječenja bio je isti na početku liječenja kao i nakon 3 i 6 mj
terapije. Prije terapije median HCV NS3-CINGVCWTV specifični CD8+ T
limfocita bio je 0.10% (raspon 0.00-0.70%) a nakon 6 mj liječenja medijan je bio
0.10 (raspon 0.00-0.30%) i bez statistički značajnih razlika između SVR i non-
SVR tako da se ta metoda nije pokazala kao mogući dobar predikcijski faktor za
SVR u kliničkoj praksi. ----- Zaključak: Povišene početne vrijednosti CXCL10, a naročito CXCL10
nakon 4 tj terapije predstavljaju najbolju pozitivnu predikcijsku vrijednost za non-
SVR (ROC P=0.7942 i ROC P=0.9288). Te vrijednosti mogu predstavljati
parametar za odluke o indivualiziranoj antivirusnoj terapiji. CXCL9 u toku
terapije također je biološki prediktor za non-SVR u bolesnika s hepatitisom C.
Kemokini CXCL9 i CXCL10 imaju različitu dinamiku koncentracija u toku
liječenja pegiliranim interferonom i ribavirinom.INTRODUCTION: HCV specific immune response and successful migration
of HCV-specific T cells towards liver is essential for HCV virus control, while
concomitant recruitment of non-specific inflammatory infiltrate results in liver
damage. The recruitment of T-cells, (both specific for HCV and non-specific) is
mediated by the interaction of chemokines secreted by infected cells and
corresponding chemokine receptors on migrating leukocytes, which is one of
the key points in immune response against HCV infection. ----- AIMS AND METHODS: The aim of this study was to analyze the kinetics of
HCV specific cellular immunity and CXCL9, CXCL10 and CXCL11 chemokine
responses during therapy of chronic HCV virus infection with pegylated
interferon alfa-2a and ribavirin. The concentrations of chemokines before and
during treatment where measured and analyzed regarding presence of
sustained viral response. The frequency of HCV NS3 specific CD8+
lymphocytes was measured before and in the first 24 weeks of therapy, with
primary endpoint to determine if there is a correlation between chemokines
concentration and therapy outcome. Viral kinetic and different chemokine
concentrations in relation with hepatitis activity index and fibrosis where
analyzed at weeks 0, 4, 12, 24 of therapy to access different chemokine profiles
during therapy, especially regarding SVR or non-SVR. ----- RESULTS: 46 patients with chronic HCV virus infection were stratified in
SVR (n=20) and non-SVR group (n=26) after peg.interferon+ribavirin treatment.
CXCL10 concentrations at the beginning of therapy were higher in patients with
non-SVR. Higher values of CXCL10 where also in correlation with higher
hepatitis activity index and higher viraemia and fibrosis, but multivariate analysis
showed the highest predictive value of elevated CXCL10 for non-SVR. Elevated
values of CXCL10 at start showed positive predictive value for non-SVR
(p=0,7942). After four weeks of therapy elevated values of CXCL showed best
predictive value for non-SVR (p=0.9288).
CXCL10 concentration >252 pg/ml after 4 weeks of therapy has a sensitivity of
81,8% for non-SVR, and specificity of 91,7%, so it is a better predictor than
patients` age or fibrosis stage (F1-3 vs F4-6). CXCL9 concentrations where also
higher in non responders, while CXCL11 concentrations where non significant
for SVR.
Chemokine response for all 3 chemokines where different during therapy. In
CXCL9 we found a decreasing concentration during therapy, but significantly
different between SVR and non-SVR. CXCL10 raised in non responders at
week four (from 395 pg/ml to 424 ml/pg) in non-SVR patients, while dropped
down in SVR group (from 185 pg/ml to 156 pg/ml) at week four of therapy. After
weeks 12 and 24 concentrations dropped in both groups, but remained
statistically significant.
CXCL11 concentration did not change during therapy in both SVR and non-SVR
group. Median of HCV NS3-specific CD+8 T lymphocytes in peripheral blood
was not significantly different in the beginning of therapy (median 0.10%, range
0.00 –0.70%) and at weeks 12 and 24 (median 0.10, range 0.00 – 0.30%) with
no differences in SVR and non-SVR patients, so this method does not seem
predictive for clinical practice. ----- CONCLUSION: Elevated values of CXCL10 at the beginning and especially
at week four of therapy represent the best positive predictive value for non-
SVR. They can be used in decisions about therapy duration and discontinuation
in individually tailored therapy for chronic hepatitis C virus infection. CXCL9 is
also predictive for SVR. CXCL9, CXCL10 and CXCL11 all have different
concentration dynamics during hepatitis C virus infection treatment
- …
